Q1 26 EPS
$-0.91
BEAT +10.06%
Est. $-1.01
Q1 26 Revenue
$31.7M
BEAT +159.70%
Est. $12.2M
vs S&P Since Q1 26
+9.3%
BEATING MARKET
BEAM +11.2% vs S&P +1.8%
Market Reaction
Did BEAM Beat Earnings? Q1 2026 Results
Beam Therapeutics delivered a standout first quarter for fiscal 2026, beating Wall Street estimates on both the top and bottom lines as collaboration activity drove revenue far beyond expectations. The gene-editing company posted revenue of $31.74 mi… Read more Beam Therapeutics delivered a standout first quarter for fiscal 2026, beating Wall Street estimates on both the top and bottom lines as collaboration activity drove revenue far beyond expectations. The gene-editing company posted revenue of $31.74 million, a 324.9% increase from the year-ago quarter and well ahead of the $12.22 million consensus, while its loss per share of $0.91 came in 10.06% better than the $1.01 estimate. The primary driver was robust license and collaboration revenue, which surged from $7.47 million a year ago as pipeline partnerships gained momentum. The net loss narrowed to $94.32 million from $108.33 million in the prior-year period, even as R&D spending climbed to $104.52 million to support advancing clinical programs, most notably BEAM-302 in alpha-1 antitrypsin deficiency, where the company selected a 60 mg optimal dose and now plans to pursue an accelerated FDA approval pathway with a pivotal cohort launch expected in the second half of 2026. With $1.21 billion in cash and a BLA submission for risto-cel targeted as early as year-end 2026, Beam's management sees its runway extending into mid-2029.
Key Takeaways
- • Revenue increase driven by license and collaboration activity
- • Operating loss improvement year-over-year despite higher R&D and G&A expenses
- • Other income contributed $12.9 million including interest income and fair value adjustments
BEAM Forward Guidance & Outlook
Beam expects to initiate the BEAM-302 pivotal cohort in the second half of 2026, pursuing an accelerated approval pathway based on FDA feedback, with approximately 50 additional patients with AATD-associated lung disease. A BLA submission for risto-cel in sickle cell disease is expected as early as year-end 2026. An IND application for BEAM-304 in PKU is anticipated in 2026. Initial clinical data from BEAM-301 in GSDIa are expected in 2026. The Phase 1 trial of BEAM-103 is expected to complete dosing in the first half of 2026. Cash, cash equivalents and marketable securities of $1.2 billion, along with an anticipated additional $100 million from the Sixth Street facility, are expected to fund operating plans into mid-2029, through the anticipated launch of risto-cel, execution of the BEAM-302 pivotal development plan, and clinical proof of concept for BEAM-304.
BEAM YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
“The first quarter of 2026 was a defining period for Beam, marked by meaningful clinical advances across our portfolio and key steps toward becoming a commercial-stage company. The updated topline data from BEAM-302 – including robust increases in total AAT and a well-tolerated safety profile – give us high confidence in the 60 mg optimal biological dose and a clear path to initiating the pivotal cohort in the second half of this year.”
— John Evans, Q1 2026 Earnings Press Release
BEAM Earnings Trends
BEAM vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BEAM EPS Trend
Earnings per share: estimate vs actual
BEAM Revenue Trend
Quarterly revenue: estimate vs actual
BEAM Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $-1.01 | $-0.91 | +10.06% | $31.7M | +159.70% |
| Q4 25 BEAT FY | $-1.12 | $2.33 | +308.97% | $114.1M | +781.34% |
| FY Full Year | $-4.28 | $-0.81 | +81.08% | $139.7M | +262.99% |
| Q3 25 MISS | $-1.03 | $-1.10 | -7.10% | $9.7M | -23.79% |
| Q2 25 BEAT | $-1.09 | $-1.00 | +8.37% | $8.5M | -36.31% |
| Q1 25 MISS | $-1.17 | $-1.24 | -5.86% | $7.5M | -49.13% |